Last reviewed · How we verify
Trovert (PEGVISOMANT)
Pegvisomant works by binding to the growth hormone receptor, blocking the action of growth hormone and preventing excessive growth and cell division.
At a glance
| Generic name | PEGVISOMANT |
|---|---|
| Sponsor | Pfizer |
| Drug class | Growth Hormone Receptor Antagonist |
| Target | Growth hormone receptor |
| Modality | Recombinant protein |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 2003 |
Mechanism of action
Imagine your body has a lock on the growth hormone receptor, and pegvisomant is the key that blocks the lock. This prevents growth hormone from doing its job, which is to stimulate growth and cell division. As a result, the excessive growth and symptoms of acromegaly are reduced.
Approved indications
- Acromegaly
Common side effects
- Insulin-like growth factor increased
- Blood growth hormone increased
- Needle issue
- Insulin-like growth factor abnormal
- Pituitary tumour
- Lipohypertrophy
- Injection site bruising
- Injection site pain
- Product dose omission issue
- Insulin-like growth factor decreased
- Injection site hypertrophy
- Injection site mass
Key clinical trials
- Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance (PHASE2)
- Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess (PHASE3)
- Effects of Pasireotide Lar Therapy on Bone Metabolism
- Korean Regulatory Post Marketing Surveillance for Somavert
- PegvisOMant and the Immune SystEm (PROMISE)
- The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly
- Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
- Growth Hormone as a Model for Reversible Activation of Adipose Tissue Fibrosis (NA)
Patents
| Patent | Expiry | Type |
|---|---|---|
| Biologic Exclusivity |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trovert CI brief — competitive landscape report
- Trovert updates RSS · CI watch RSS
- Pfizer portfolio CI